Comparing the Efficacy of Lyophilized Self Growth Factor Versus PRP Injection for Knee OA
Key facts
- Where
- Taipei, TaiwanSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 80 years old?
Source: NCT06932614, who can take part
Where in Taiwan
- No. 325, Sec. 2, Chenggong Rd., Neihu Dist.Taipei, TaiwanContact: Yu Chi Su, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Tri-Service General Hospital (TSGH)
- Trial code
- NCT06932614
- Record updated
- 10 September 2025
- Original description
Knee osteoarthritis(OA) is a common degenerative joint disease that often leads to knee pain, stiffness, and a decline in quality of life among middle-aged and elderly individuals. Platelet-rich plasma (PRP) is a regenerative treatment method that involves drawing a small amount of the patient's own blood and using centrifugation process to produce PRP. PRP, which is rich in growth factors and anti-inflammatory cytokines, facilitate the repair of damaged tissues and has been used in treating knee OA. Self-repair factor (SRF), an advanced form of PRP, is created using multi-step centrifugation and proprietary processes to increase platelet concentration. This enhancement may offer superior repair efficacy and faster recovery compared to traditional PRP. To explore this potential, we designed a randomized, double-blind, clinical trial to compare the effectiveness of SRF and PRP in treating degenerative knee osteoarthritis.Read full original descriptionShow less
Comparing the Efficacy of Lyophilized Self Growth Factor Versus Platelet-Rich Plasma(PRP) Injection for Knee Osteoarthritis: A Prospective, Double-Blind, Randomized Controlled Trial
Knee osteoarthritis(OA) is a common degenerative joint disease that often leads to knee pain, stiffness, and a decline in quality of life among middle-aged and elderly individuals. Platelet-rich plasma (PRP) is a regenerative treatment method that involves drawing a small amount of the patient's own blood and using centrifugation process to produce PRP. PRP, which is rich in growth factors and anti-inflammatory cytokines, facilitate the repair of damaged tissues and has been used in treating knee OA. Self-repair factor (SRF), an advanced form of PRP, is created using multi-step centrifugation and proprietary processes to increase platelet concentration. This enhancement may offer superior repair efficacy and faster recovery compared to traditional PRP. To explore this potential, we designed a randomized, double-blind, clinical trial to compare the effectiveness of SRF and PRP in treating degenerative knee osteoarthritis.
Inclusion: Male or female, aged over 20 and under 80; Consciousness clear and able to communicate; Unilateral or bilateral osteoarthritis of the knee with symptoms lasting more than 3 months; X-ray imaging shows mild to moderate knee osteoarthritis (Kellgren-Lawrence grades 1-3); Knee joint pain with a Visual Analogue Scale (VAS) score greater than 4.
Exclusion: Received hyaluronic acid or corticosteroid intraarticular injections within the past six months, or received NSAIDs or oral corticosteroid treatment within 7 days prior to treatment; The treated joint has undergone joint replacement surgery or major surgery; Currently receiving anticoagulant therapy; Currently systemic infection; History of HIV/AIDS, syphilis, or other legally notifiable infectious diseases; Known history of cancers, rheumatoid arthritis, platelet dysfunction, thrombocytopenia, hypofibrinogenemia, acute or chronic infectious diseases, chronic liver disease, or poorly controlled cardiovascular disease or diabetes; Severe knee osteoarthritis (Kellgren-Lawrence grade 4); Severe knee deformity or instability; Long-term or excessive use of aspirin or vitamin E; Pregnant or breastfeeding women, or women and men of childbearing potential who are unable to use effective contraception during the treatment period; Deemed unsuitable for participation in the trial by the principal investigator; Unable to sign the informed consent form.